{"title": "Preliminary estimation of the novel coronavirus disease (COVID-19) cases in Iran: a modelling analysis based on overseas cases and air travel data", "doi": "10.1101/2020.03.02.20030320", "citation_id": "2020.03.02.20030320v1", "date": "2020-03-06", "laguage": "en", "journal_title": "medRxiv", "first_page": "2020.03.02.20030320", "abstract": "<p>As of 1 March 2020, Iran has reported 987 COVID-19 cases and including 54 associated deaths. At least six neighboring countries (Bahrain, Iraq, Kuwait, Oman, Afghanistan and Pakistan) have reported imported COVID-19 cases from Iran. We used air travel data and the cases from Iran to other Middle East countries and estimated 16533 (95% CI: 5925, 35538) COVID-19 cases in Iran by 25 February, before UAE and other Gulf Cooperation Council countries suspended inbound and outbound flights from Iran.</p>", "twitter_description": "As of 1 March 2020, Iran has reported 987 COVID-19 cases and including 54 associated deaths. At least six neighboring countries (Bahrain, Iraq, Kuwait, Oman, Afghanistan and Pakistan) have reported imported COVID-19 cases from Iran. We used air travel data and the cases from Iran to other Middle East countries and estimated 16533 (95% CI: 5925, 35538) COVID-19 cases in Iran by 25 February, before UAE and other Gulf Cooperation Council countries suspended inbound and outbound flights from Iran.\n\n### Competing Interest Statement\n\nDH was supported by an Alibaba (China) - Hong Kong Polytechnic University Collaborative Research project. Other authors declare no competing interests. \n\n### Funding Statement\n\nDH was supported by General Research Fund (15205119) of Research Grants Council of Hong Kong and an Alibaba-Hong Kong Polytechnic University Collaborative Research project. The funding agencies had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; or decision to submit the manuscript for publication. \n\n### Author Declarations\n\nAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.\n\nYes\n\nAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.\n\nYes\n\nI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).\n\nYes\n\nI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.\n\nYes\n\nWe used only publicly available data.", "full_text_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20030320v1.full", "public_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20030320v1", "abstract_html_url": "https://www.medrxiv.org/content/10.1101/2020.03.02.20030320v1.abstract", "pdf_url": "https://www.medrxiv.org/content/medrxiv/early/2020/03/06/2020.03.02.20030320.full.pdf", "rights": "\u00a9 2020, Posted by Cold Spring Harbor Laboratory. This pre-print is available under a Creative Commons License (Attribution-NonCommercial-NoDerivs 4.0 International), CC BY-NC-ND 4.0, as described at http://creativecommons.org/licenses/by-nc-nd/4.0/", "publisher": "Cold Spring Harbor Laboratory Press", "pisa": "medrxiv;2020.03.02.20030320v1", "access_rights": "restricted", "authors": ["Zian Zhuang", "Shi Zhao", "Qianying Lin", "Peihua Cao", "Yijun Lou", "Lin Yang", "Daihai He"]}